Rapid succession of peripheral blood progenitor cell mobilization cycles in patients with chronic heart failure: effects on the hematopoietic system

BACKGROUND: Circulating hematopoietic peripheral blood progenitor cells (PBPCs) may contribute to the regeneration of nonhematopoietic organs. An increase in circulating PBPC numbers may enhance this process. Therefore, an exploratory trial of repeated PBPC mobilization in patients with chronic heart failure was conducted. The safety and cardiovascular efficacy data have been described elsewhere. In the hematopoietic system, the trial offered an opportunity to study several new aspects of granulocyte–colony‐stimulating factor (G‐CSF) action.

[1]  J. Stypmann,et al.  Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure--Feasibility, safety and effects on exercise tolerance and cardiac function. , 2006, Basic research in cardiology.

[2]  H. Johnsen,et al.  Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. , 2005, International journal of cardiology.

[3]  J. Stypmann,et al.  Granulocyte colony–stimulating factor–induced blood stem cell mobilisation in patients with chronic heart failure , 2005, Basic Research in Cardiology.

[4]  Z. Estrov,et al.  Adult stem cells for tissue repair - a new therapeutic concept? , 2003, The New England journal of medicine.

[5]  A. Hüttmann,et al.  Bone marrow-derived stem cells and "plasticity" , 2003, Annals of Hematology.

[6]  James T. Willerson,et al.  Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure , 2003, Circulation.

[7]  Hung-Fat Tse,et al.  Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation , 2003, The Lancet.

[8]  Bernd Westphal,et al.  Autologous bone-marrow stem-cell transplantation for myocardial regeneration , 2003, The Lancet.

[9]  C. Nakaseko,et al.  Mobilization factors of peripheral blood stem cells in healthy donors. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[10]  I. Petit,et al.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. , 2002, Experimental hematology.

[11]  J. Auer,et al.  Amiodarone in the prevention and treatment of arrhythmia. , 2002, Current opinion in investigational drugs.

[12]  H. Kasanuki,et al.  Amiodarone distribution in human tissues after long-term therapy: a case of arrhythmogenic right ventricular cardiomyopathy , 2002, Heart and Vessels.

[13]  A. Verdeguer,et al.  Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors , 2002, Transfusion.

[14]  Federica Limana,et al.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Stroncek,et al.  Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone , 2001, Transfusion.

[16]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[17]  A. Fauser,et al.  Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study , 2000, Bone Marrow Transplantation.

[18]  A. Gratwohl,et al.  Repeated peripheral stem cell mobilization in healthy donors: time‐dependent changes in mobilization efficiency , 1999, British journal of haematology.

[19]  M. Holm.  Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. , 1998, Journal of hematotherapy.

[20]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.

[21]  P. Anderlini,et al.  The Use of Mobilized Peripheral Blood Stem Cells from Normal Donors for Allografting , 1997, Stem Cells.

[22]  J. Gabrilove,et al.  Filgrastim (r-metHuG-CSF): the first 10 years. , 1996, Blood.

[23]  J. B. Hutchins,et al.  Amiodarone-induced lymphocyte toxicity and mitochondrial function. , 1996, Journal of cardiovascular pharmacology.

[24]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[25]  D. Stroncek,et al.  Changes in blood counts after the administration of granulocyte‐colony‐ stimulating factor and the collection of peripheral blood stem cells from healthy donors , 1996, Transfusion.

[26]  R. Champlin,et al.  Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.

[27]  M. Andreeff,et al.  Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.

[28]  J. Gabrilove,et al.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. , 1993, Blood.

[29]  Y. Niitsu,et al.  Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. , 1993, Bone marrow transplantation.

[30]  R Storb,et al.  The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. , 1993, Blood.

[31]  F. Herrmann,et al.  Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. , 1989, Blood.

[32]  J. Villeval,et al.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.

[33]  J. Gabrilove,et al.  Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. , 1988, The Journal of clinical investigation.

[34]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[35]  D. Crowther,et al.  Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. , 1987, British Journal of Cancer.

[36]  M. Vadas,et al.  Hemopoietic colony-stimulating factors. , 1984, Immunology today.

[37]  J. Goldman,et al.  Transfusion of circulating stem cells. , 1984, Critical reviews in clinical laboratory sciences.